Mark Stenhouse, Board Observer & Advisor to Abivax, said: “I am impressed with the clinical profile of obefazimod and its potential to address unmet needs in the patient community ... recipients as a ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

common share at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $1.81 per share. The combined offering price of each ...

This study involved 182 LockeT devices deployed in over 100 patients, with outstanding clinical results ... The company announced on October 25, 2024, the exercise of outstanding warrants resulting in ...

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology ...

CalciMedica expects to enroll 150 patients with stage ... benefits of Auxora for the treatment of AP, AKI and AIPT; the potential for additional proceeds from the underwritten public offering if the ...

To court, the nature of the patient’s injuries and the resultant effect on her social, family and emotional life could not be ...

I add this one exercise to my stretching routine whenever I need to loosen tight quads and hips. A variation of runner’s ...

Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures ... which is designed to aggregate patient data from across the ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

New protein immunostaining and mass spectrometry analyses that were presented, confirmed the production of both collagen a4 (IV) and collagen a5 (IV) proteins in NMAS patients treated with ELX-02.